|
Volumn 163, Issue 3, 2015, Pages 226-228
|
Limited access to new hepatitis C virus treatment under state medicaid programs
|
Author keywords
[No Author keywords available]
|
Indexed keywords
SOFOSBUVIR;
ANTIVIRUS AGENT;
URIDINE PHOSPHATE;
BUDGET;
CONSULTATION;
COST EFFECTIVENESS ANALYSIS;
DRUG APPROVAL;
DRUG SCREENING;
FOOD AND DRUG ADMINISTRATION;
HEALTH CARE ACCESS;
HEPATITIS C;
HEPATITIS C VIRUS;
HUMAN;
MEDICAID;
MEDICAL SOCIETY;
META ANALYSIS (TOPIC);
NOTE;
PRACTICE GUIDELINE;
PRIORITY JOURNAL;
UNSPECIFIED SIDE EFFECT;
ANALOGS AND DERIVATIVES;
DRUG COST;
ECONOMICS;
HEALTH CARE POLICY;
HEPATITIS C, CHRONIC;
ORGANIZATION AND MANAGEMENT;
REIMBURSEMENT;
UNITED STATES;
ANTIVIRAL AGENTS;
BUDGETS;
DRUG COSTS;
ELIGIBILITY DETERMINATION;
HEALTH POLICY;
HEPATITIS C, CHRONIC;
HUMANS;
INSURANCE, HEALTH, REIMBURSEMENT;
MEDICAID;
SOFOSBUVIR;
UNITED STATES;
URIDINE MONOPHOSPHATE;
|
EID: 84938809007
PISSN: 00034819
EISSN: 15393704
Source Type: Journal
DOI: 10.7326/M15-0320 Document Type: Note |
Times cited : (122)
|
References (7)
|